Switching to low dose of plasma-derived factor VIII/vWF concentrates with Confact®-F as salvage immune tolerance induction in haemophilia A patients with inhibitors: five case reports from Japan

被引：1
|
作者：
Nagao, A. [1 ]
Oka, T. [2 ]
Hanabusa, H. [1 ]
机构：
[1] Ogikubo Hosp, Dept Hematol, Suginami Ku, Tokyo 1670035, Japan
[2] Sapporo Tokushukai Hosp, Dept Pediat, Sapporo, Hokkaido, Japan
来源：
HAEMOPHILIA | 2015年 / 21卷 / 05期
关键词：
VON-WILLEBRAND-FACTOR;
D O I：
10.1111/hae.12728
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E425 / E427
页数：3
相关论文
共 21 条
  • [1] Immune tolerance induction (ITI) according to the Bonn protocol in haemophilia A patients with inhibitors using a plasma-derived VWF-containing factor VIII concentrate: two paediatric case reports
    Lohse, J.
    Gehrisch, S.
    Escuriola-Ettingshausen, C.
    Kreuz, W.
    Knoefler, R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 1073 - 1074
  • [2] Successful Low-Dose Immune Tolerance Induction Regimen Using Multiple Plasma-Derived Factor VIII Concentrates
    Colella, M.
    Montalvao, S.
    Sambo, A.
    De Paula, E.
    Ozelo, M.
    HAEMOPHILIA, 2012, 18 : 92 - 92
  • [3] Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors
    Unuvar, A.
    Kavakli, K.
    Baytan, B.
    Kazanci, E.
    Sayli, T.
    Oren, H.
    Celkan, T.
    Gursel, T.
    HAEMOPHILIA, 2008, 14 (02) : 315 - 322
  • [4] Immune Tolerance Induction (ITI) with a Plasma-Derived Factor VIII for Patients with Hemophilia a and Inhibitors: A Retrospective Study
    Escobar, Miguel A.
    Shaffer, Linda
    Holguin, Mark
    McCavit, Timothy
    Rajan, Sandeep K.
    Amega, Novinyo
    BLOOD, 2019, 134
  • [5] Case study immune-tolerance in haemophilia a using plasma-derived factor VIII concentrate
    Needham, J.
    Roy, A.
    Knight, S.
    Stebbings, Y.
    Rangarajan, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1133 - 1134
  • [6] Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates
    Scharrer, I
    Bray, GL
    Neutzling, O
    HAEMOPHILIA, 1999, 5 (03) : 145 - 154
  • [7] Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors
    Jimenez-Yuste, V.
    Oldenburg, J.
    Rangarajan, S.
    Kurth, M. H.
    Bozzo, J.
    Santagostino, E.
    HAEMOPHILIA, 2016, 22 (01) : E71 - E74
  • [8] Low incidence of FVIII inhibitors in patients treated with plasma derived FVIII concentrates and the outcomes of immune tolerance induction with FVIII/vWF concentrates
    Batorova, Angelika
    Bubanska, Eva
    Morongova, Anna
    Jankovicova, Denisa
    Prigancova, Tatiana
    HAEMOPHILIA, 2014, 20 : 47 - 48
  • [9] Lower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments
    Biron-Andreani, Christine
    Diaz, Isabelle
    Navarro, Robert
    Schved, Jean-Francois
    HEMATOLOGIE, 2019, 25 (02): : 93 - 99
  • [10] Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors
    Orsini, Frederique
    Rotschild, Chantal
    Beurrier, Philippe
    Faradji, Albert
    Goudemand, Jenny
    Polack, Benoit
    HAEMATOLOGICA, 2005, 90 (09) : 1288 - +
123